



MARKET RELEASE

23 August 2017

Noxopharm Limited

SUSPENSION FROM OFFICIAL QUOTATION

The securities of Noxopharm Limited (the “Company”) will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

Security Code: NOX

Cheng Tang
SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



Date: 23 August 2017

Sydney, Australia

Ms Cheng Tang
Senior Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au
tradinghaltsmelbourne@asx.com.au

NOXOPHARM LIMITED – REQUEST FOR VOLUNTARY SUSPENSION

In accordance with Listing Rule 17.2, the Company requests a voluntary suspension on its securities (NOX) effective immediately, pending the release of an announcement in relation to completion of the proposed capital raising.

The voluntary suspension is requested until the release of an announcement regarding the completion and finalisation of paperwork for the capital raising which is expected to be made within the next 24 hours.

The Company is not aware of any reason why the voluntary suspension should not be granted.

Thank you for your assistance.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'D Franks', with a long horizontal flourish underneath.

David Franks
Company Secretary

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director